Capricor Therapeutics (NASDAQ:CAPR) Rating Lowered to Sell at Wall Street Zen

Capricor Therapeutics (NASDAQ:CAPR) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

CAPR has been the topic of several other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Capricor Therapeutics in a research note on Monday, December 29th. UBS Group set a $50.00 price target on Capricor Therapeutics in a research report on Monday, December 15th. Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Industrial Alliance Securities set a $48.00 price objective on Capricor Therapeutics in a research note on Wednesday, December 3rd. Finally, Piper Sandler reissued an “overweight” rating and set a $45.00 target price (up previously from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Capricor Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $40.82.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR opened at $23.84 on Friday. The company has a 50 day simple moving average of $17.95 and a 200 day simple moving average of $11.07. Capricor Therapeutics has a 1 year low of $4.30 and a 1 year high of $40.37. The firm has a market cap of $1.09 billion, a PE ratio of -13.24 and a beta of 0.22.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.54). As a group, research analysts anticipate that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. GoalVest Advisory LLC bought a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $59,000. PVG Asset Management Corp bought a new position in Capricor Therapeutics during the third quarter worth $91,000. Voleon Capital Management LP acquired a new stake in Capricor Therapeutics in the third quarter worth $311,000. Moneta Group Investment Advisors LLC increased its stake in Capricor Therapeutics by 25.5% in the third quarter. Moneta Group Investment Advisors LLC now owns 34,454 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 7,000 shares in the last quarter. Finally, Brevan Howard Capital Management LP acquired a new position in shares of Capricor Therapeutics during the third quarter valued at about $123,000. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.